Avalo Therapeutics, Inc. (AVTX) 10-Year Financial Performance & Capital Metrics

AVTX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutAvalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Show more

Revenue $441K -77.1%
EBITDA -$68M -151.3%
Net Income -$35M -11.4%
EPS (Diluted) -3.26 +97.1%
Gross Margin 182.99% +450.1%
EBITDA Margin -15497.28% -996.5%
Operating Margin -15535.6% -992.8%
Net Margin -7965.76% -385.9%
ROE -50.06% +88.4%
ROIC -
Debt/Equity 0.00 -94.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.3x book value

✗Weaknesses

✗Negative free cash flow
✗Sales declining 42.1% over 5 years
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-42.05%

3Y-56.61%

TTM-76.59%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1155.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM103.75%

ROCE

10Y Avg-102.45%

5Y Avg-143.26%

3Y Avg-129.39%

Latest-85.56%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.15M	27.81M	18.33M	6.75M	6.7M	5.4M	18.05M	1.92M	441K
Revenue Growth %	-	-	23.12%	-0.34%	-0.63%	-0.01%	-0.19%	2.34%	-0.89%	-0.77%
Cost of Goods Sold+	23.51K	8.24M	635.65K	7.48M	-566.52K	300K	1.49M	3.43M	1.28M	-366K
COGS % of Revenue	-	7.15%	0.02%	0.41%	-0.08%	0.04%	0.28%	0.19%	0.67%	-0.83%
Gross Profit+	-23.51K	-7.09M	27.18M	10.85M	7.32M	6.4M	3.91M	14.62M	640K	807K
Gross Margin %	-	-6.15%	0.98%	0.59%	1.08%	0.96%	0.72%	0.81%	0.33%	1.83%
Gross Profit Growth %	1%	-300.43%	4.84%	-0.6%	-0.33%	-0.13%	-0.39%	2.74%	-0.96%	0.26%
Operating Expenses+	11.01M	17.23M	13.29M	29.52M	23.45M	6.4M	86.04M	52.06M	27.99M	69.32M
OpEx % of Revenue	-	14.95%	0.48%	1.61%	3.47%	0.96%	15.94%	2.88%	14.55%	157.19%
Selling, General & Admin	4.42M	7.08M	8.91M	19.2M	11.61M	19.76M	24.66M	20.71M	10.3M	17.24M
SG&A % of Revenue	-	6.14%	0.32%	1.05%	1.72%	2.95%	4.57%	1.15%	5.35%	39.1%
Research & Development	6.59M	10.15M	4.37M	5.79M	11.76M	32.19M	59.84M	31.31M	13.78M	52.08M
R&D % of Revenue	-	8.8%	0.16%	0.32%	1.74%	4.81%	11.08%	1.73%	7.16%	118.09%
Other Operating Expenses	0	0	0	13.66K	83.11K	-45.55M	1.55M	38K	3.91M	0
Operating Income+	-11.01M	-16.08M	13.89M	-39.31M	-16.14M	0	-82.13M	-37.44M	-27.35M	-68.51M
Operating Margin %	-	-13.95%	0.5%	-2.15%	-2.39%	-	-15.22%	-2.07%	-14.22%	-155.36%
Operating Income Growth %	0.36%	-0.46%	1.86%	-3.83%	0.59%	1%	-	0.54%	0.27%	-1.5%
EBITDA+	-10.99M	-16.05M	14.32M	-37.46M	-12.25M	-45.45M	-80.48M	-37.27M	-27.19M	-68.34M
EBITDA Margin %	-	-13.92%	0.51%	-2.04%	-1.82%	-6.78%	-14.91%	-2.06%	-14.13%	-154.97%
EBITDA Growth %	0.36%	-0.46%	1.89%	-3.62%	0.67%	-2.71%	-0.77%	0.54%	0.27%	-1.51%
D&A (Non-Cash Add-back)	23.51K	26.86K	425.48K	1.85M	3.88M	1.84M	1.66M	166K	158K	169K
EBIT	-10.48M	-16.08M	13.89M	-14.9M	-17.39M	-47.29M	-82.13M	-37.44M	-23.44M	-68.51M
Net Interest Income+	-793.21K	-464.18K	-24.02K	16.26K	121.33K	49K	-2.39M	-4.17M	-3.42M	3.32M
Interest Income	0	0	0	16.26K	121.33K	49K	0	0	0	3.32M
Interest Expense	793.21K	464.18K	24.02K	0	0	0	2.39M	4.17M	3.42M	0
Other Income/Expense	519.84K	-391.56K	-53.64K	54.93K	147.29K	-67.18M	-2.41M	-4.19M	-4.18M	33.5M
Pretax Income+	-10.49M	-16.47M	13.84M	-40.09M	-15.99M	-67.18M	-84.55M	-41.63M	-31.53M	-35.02M
Pretax Margin %	-	-14.29%	0.5%	-2.19%	-2.37%	-10.03%	-15.66%	-2.31%	-16.39%	-79.4%
Income Tax+	-543.51K	364.14K	1.97M	-33.91K	280.32K	-2.79M	-196K	28K	14K	114K
Effective Tax Rate %	1%	1%	0.86%	1%	1.01%	0.95%	1%	1%	1%	1%
Net Income+	-10.49M	-16.47M	11.87M	-40.05M	-16.07M	-63.5M	-84.38M	-41.66M	-31.54M	-35.13M
Net Margin %	-	-14.29%	0.43%	-2.19%	-2.38%	-9.48%	-15.63%	-2.31%	-16.4%	-79.66%
Net Income Growth %	0.35%	-0.57%	1.72%	-4.37%	0.6%	-2.95%	-0.33%	0.51%	0.24%	-0.11%
Net Income (Continuing)	-10.49M	-16.47M	11.87M	-35.27M	-16.27M	-64.38M	-84.35M	-41.66M	-31.54M	-35.13M
Discontinued Operations	0	0	0	0	198.21K	884K	-27K	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-16.21	-21.93	1822.74	-3317.28	-819.74	-2523.77	-2330.66	-1062.65	-113.58	-3.26
EPS Growth %	0.61%	-0.35%	84.12%	-2.82%	0.75%	-2.08%	0.08%	0.54%	0.89%	0.97%
EPS (Basic)	-16.21	-21.93	1856.88	-3317.28	-819.74	-2523.77	-2330.66	-1062.65	-113.58	-4.32
Diluted Shares Outstanding	773	3.07K	6.51K	12.07K	19.85K	25.51K	36.19K	39.2K	277.73K	10.78M
Basic Shares Outstanding	773	3.07K	6.39K	12.07K	19.85K	25.51K	36.19K	39.2K	277.73K	8.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.62M	5.66M	10.99M	21.93M	17.72M	26M	61.84M	16.42M	8.39M	138.89M
Cash & Short-Term Investments	21.16M	5.13M	2.47M	10.65M	11.24M	18.92M	54.59M	13.17M	7.42M	134.55M
Cash Only	21.16M	5.13M	2.47M	10.65M	3.61M	18.92M	54.59M	13.17M	7.42M	134.55M
Short-Term Investments	0	0	0	0	7.63M	0	0	0	0	0
Accounts Receivable	0	132.47K	2.94M	6.08M	5.24M	4.38M	4.8M	1.92M	136K	611K
Days Sales Outstanding	-	41.94	38.52	121.18	283.45	238.92	324.5	38.8	25.8	505.7
Inventory	0	11K	382.15K	1.11M	21.33K	3K	38K	20K	0	0
Days Inventory Outstanding	-	0.49	219.44	54.22	-13.75	3.65	9.3	2.13	-	-
Other Current Assets	58.83K	11.11K	4.18M	9.41M	515.11K	38K	51K	1.3M	844K	3.73M
Total Non-Current Assets+	35K	106K	32.13M	48.32M	18.38M	17.75M	18.37M	16.95M	12.6M	11.84M
Property, Plant & Equipment	35K	43K	44.61K	586.51K	1.45M	1.61M	2.69M	2.41M	1.97M	1.21M
Fixed Asset Turnover	-	26.81x	623.45x	31.25x	4.66x	4.17x	2.00x	7.49x	0.98x	0.36x
Goodwill	0	0	14.29M	16.41M	14.41M	14.41M	14.41M	14.41M	10.5M	10.5M
Intangible Assets	0	0	17.66M	31.24M	2.43M	1.58M	38K	0	0	0
Long-Term Investments	0	62.83K	131.35K	81.72K	0	0	0	0	0	0
Other Non-Current Assets	0	173	131.35K	-91.24K	101.94K	149K	1.23M	131K	131K	131K
Total Assets+	21.66M	5.77M	43.12M	70.25M	36.11M	43.76M	80.21M	33.37M	20.99M	150.73M
Asset Turnover	-	0.20x	0.64x	0.26x	0.19x	0.15x	0.07x	0.54x	0.09x	0.00x
Asset Growth %	0.76%	-0.73%	6.48%	0.63%	-0.49%	0.21%	0.83%	-0.58%	-0.37%	6.18%
Total Current Liabilities+	5.85M	4.31M	11.41M	26.22M	12.16M	15.22M	19.89M	22.11M	4.62M	6.96M
Accounts Payable	678.11K	1.01M	1.3M	1.45M	2.08M	2.57M	3.37M	2.88M	446K	283K
Days Payables Outstanding	10.53K	44.75	745.9	70.58	-1.34K	3.13K	824.74	306.33	126.78	-282.23
Short-Term Debt	3.21M	2.35M	0	0	0	0	0	5.93M	0	0
Deferred Revenue (Current)	1000K	942.57K	0	1000K	0	0	0	88K	0	0
Other Current Liabilities	835.56K	675.39K	8.71M	21.14M	5.57M	4.57M	4.32M	3.18M	3.06M	3.24M
Current Ratio	3.70x	1.31x	0.96x	0.84x	1.46x	1.71x	3.11x	0.74x	1.82x	19.96x
Quick Ratio	3.70x	1.31x	0.93x	0.79x	1.46x	1.71x	3.11x	0.74x	1.82x	19.96x
Cash Conversion Cycle	-	-2.33	-487.94	104.81	1.61K	-2.89K	-490.94	-265.4	-	-
Total Non-Current Liabilities+	8.57M	1.25M	3.86M	23.13M	2.95M	3.97M	37.24M	22.17M	9.07M	10.74M
Long-Term Debt	2.35M	0	0	0	0	0	32.83M	13.49M	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	7.14K	69.24K	85.98K	90K	113K	141K	155K	270K
Other Non-Current Liabilities	370.54K	1.25M	3.85M	23.06M	2.87M	3.88M	4.3M	8.54M	8.92M	10.47M
Total Liabilities	8.57M	5.56M	15.26M	49.34M	15.11M	19.19M	57.13M	44.28M	13.69M	17.7M
Total Debt+	5.56M	2.35M	0	15.38M	155.81K	426K	33.32M	19.95M	537K	568K
Net Debt	-15.6M	-2.77M	-2.47M	4.73M	-3.45M	-18.49M	-21.27M	6.78M	-6.88M	-133.98M
Debt / Equity	0.43x	11.37x	-	0.74x	0.01x	0.02x	1.44x	-	0.07x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-0.17x	-	-	-	-	-	-	-
Interest Coverage	-13.88x	-34.64x	578.36x	-	-	-	-34.35x	-8.98x	-8.00x	-
Total Equity+	13.08M	207K	27.86M	20.91M	21M	24.56M	23.08M	-10.91M	7.3M	133.03M
Equity Growth %	1.5%	-0.98%	133.59%	-0.25%	0%	0.17%	-0.06%	-1.47%	1.67%	17.21%
Book Value per Share	16927.91	67.51	4278.14	1731.63	1057.76	962.80	637.78	-278.43	26.30	12.34
Total Shareholders' Equity	13.08M	207K	27.86M	20.91M	21M	24.56M	23.08M	-10.91M	7.3M	133.03M
Common Stock	8.65K	9.43K	2.69M	40.8K	44.38K	75K	9K	0	1K	10K
Retained Earnings	-53.56M	-70.04M	-58.17M	-98.22M	-114.29M	-177.79M	-262.17M	-303.82M	-335.13M	-370.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-21.66B	0	2.66M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.16M	-14.57M	12.52M	-3.13M	-19.13M	-40.54M	-70.89M	-26.75M	-30.68M	-49.06M
Operating CF Margin %	-	-12.64%	0.45%	-0.17%	-2.83%	-6.05%	-13.13%	-1.48%	-15.95%	-111.24%
Operating CF Growth %	0.35%	-0.43%	1.86%	-1.25%	-5.12%	-1.12%	-0.75%	0.62%	-0.15%	-0.6%
Net Income	-10.49M	-16.47M	11.87M	-40.05M	-16.07M	-63.5M	-84.38M	-41.66M	-31.54M	-35.13M
Depreciation & Amortization	23.51K	26.86K	425.48K	4.55M	3.88M	1.84M	1.66M	166K	158K	169K
Stock-Based Compensation	394.75K	1.69M	1.16M	2.43M	2.53M	6.79M	8.17M	0	3.48M	5.85M
Deferred Taxes	-1.31M	-72.63K	-832.63K	-16.75K	16.74K	197K	22K	28K	14K	114K
Other Non-Cash Items	293.75K	162.27K	366.23K	21.22M	-7.47M	18.57M	794K	14.77M	6.46M	-15.35M
Working Capital Changes	927.77K	87.07K	-466.75K	8.73M	-2.03M	-4.44M	2.84M	-60K	-9.24M	-4.71M
Change in Receivables	0	-132.47K	-247.19K	-222.53K	6.78M	-2.79M	1.12M	2.88M	1.78M	-475K
Change in Inventory	0	0	-202.62K	-311.2K	532.95K	18K	-35K	18K	20K	0
Change in Payables	-268.71K	332.1K	96.06K	82.45K	1.02M	99K	796K	-487K	-2.44M	-163K
Cash from Investing+	-19.98K	-34.88K	-18.91M	865.46K	-443K	11.13M	-113K	-95K	-133K	356K
Capital Expenditures	-19.98K	-34.88K	-23.32K	-564.41K	-262.01K	-63K	-113K	-95K	-158K	0
CapEx % of Revenue	-	0.03%	0%	0.03%	0.04%	0.01%	0.02%	0.01%	0.08%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-1K	-180.99K	0	0	0	25K	0
Cash from Financing+	19.6M	-1.43M	3.74M	10.4M	12.56M	44.78M	106.76M	-14.7M	25.04M	175.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.27M	-114.94K	-232.38K	6.55M	131.07K	332K	1.93M	0	67K	60.22M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.18M	-14.61M	12.5M	-3.69M	-19.4M	-40.6M	-71M	-26.85M	-30.84M	-49.06M
FCF Margin %	-	-12.67%	0.45%	-0.2%	-2.87%	-6.06%	-13.15%	-1.49%	-16.03%	-111.24%
FCF Growth %	0.34%	-0.43%	1.86%	-1.3%	-4.25%	-1.09%	-0.75%	0.62%	-0.15%	-0.59%
FCF per Share	-13175.11	-4764.35	1918.91	-305.82	-977.20	-1591.55	-1961.95	-684.81	-111.04	-4.55
FCF Conversion (FCF/Net Income)	0.97x	0.88x	1.05x	0.08x	1.19x	0.64x	0.84x	0.64x	0.97x	1.40x
Interest Paid	0	0	72.53K	525K	1.05M	0	0	0	0	0
Taxes Paid	0	0	540K	354K	1.8M	474K	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-80.17%	-247.85%	84.58%	-164.26%	-76.71%	-278.77%	-354.19%	-684.77%	-431.87%	-50.06%
Return on Invested Capital (ROIC)	-	-	91.3%	-115.57%	-56.06%	-	-1562.67%	-	-4815.32%	-
Gross Margin	-	-614.57%	97.71%	59.19%	108.39%	95.52%	72.38%	80.98%	33.26%	182.99%
Net Margin	-	-1428.53%	42.68%	-218.55%	-238.1%	-947.9%	-1563.1%	-230.78%	-1639.5%	-7965.76%
Debt / Equity	0.43x	11.37x	-	0.74x	0.01x	0.02x	1.44x	-	0.07x	0.00x
Interest Coverage	-13.88x	-34.64x	578.36x	-	-	-	-34.35x	-8.98x	-8.00x	-
FCF Conversion	0.97x	0.88x	1.05x	0.08x	1.19x	0.64x	0.84x	0.64x	0.97x	1.40x
Revenue Growth	-	-	2312.24%	-34.11%	-63.17%	-0.76%	-19.42%	234.4%	-89.34%	-77.08%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	6.7M	4.77M	3.36M	1.41M	441K
Product Growth	-	-	-	-28.75%	-29.52%	-58.15%	-68.68%
License	-	100K	-	625K	14.69M	516K	-
License Growth	-	-	-	-	2249.92%	-96.49%	-
Prescription Drugs	10.19M	6.65M	-	-	-	-	-
Prescription Drugs Growth	-	-34.75%	-	-	-	-	-
Sales Revenue, Product	17.87M	6.65M	-	-	-	-	-
Sales Revenue, Product Growth	-	-62.79%	-	-	-	-	-
Sales Force Revenue	456.06K	-	-	-	-	-	-
Sales Force Revenue Growth	-	-	-	-	-	-	-
Prescribed Dietary Supplements	7.68M	-	-	-	-	-	-
Prescribed Dietary Supplements Growth	-	-	-	-	-	-	-
Grant Revenue	-	-	-	-	-	-	-
Grant Revenue Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Avalo Therapeutics, Inc. (AVTX) reported $0.2M in revenue for fiscal year 2024. This represents a 132% increase from $0.1M in 2012.

Avalo Therapeutics, Inc. (AVTX) saw revenue decline by 77.1% over the past year.

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $99.9M for fiscal year 2024.

Dividend & Returns

Avalo Therapeutics, Inc. (AVTX) has a return on equity (ROE) of -50.1%. Negative ROE indicates the company is unprofitable.

Avalo Therapeutics, Inc. (AVTX) had negative free cash flow of $52.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Avalo Therapeutics, Inc. (AVTX) 10-Year Financial Performance & Capital Metrics

AVTX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $441K -77.1%
EBITDA -$68M -151.3%
Net Income -$35M -11.4%
EPS (Diluted) -3.26 +97.1%
Gross Margin 182.99% +450.1%
EBITDA Margin -15497.28% -996.5%
Operating Margin -15535.6% -992.8%
Net Margin -7965.76% -385.9%
ROE -50.06% +88.4%
ROIC -
Debt/Equity 0.00 -94.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.3x book value

✗Weaknesses

✗Negative free cash flow
✗Sales declining 42.1% over 5 years
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-42.05%

3Y-56.61%

TTM-76.59%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1155.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM103.75%

ROCE

10Y Avg-102.45%

5Y Avg-143.26%

3Y Avg-129.39%

Latest-85.56%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.15M	27.81M	18.33M	6.75M	6.7M	5.4M	18.05M	1.92M	441K
Revenue Growth %	-	-	23.12%	-0.34%	-0.63%	-0.01%	-0.19%	2.34%	-0.89%	-0.77%
Cost of Goods Sold+	23.51K	8.24M	635.65K	7.48M	-566.52K	300K	1.49M	3.43M	1.28M	-366K
COGS % of Revenue	-	7.15%	0.02%	0.41%	-0.08%	0.04%	0.28%	0.19%	0.67%	-0.83%
Gross Profit+	-23.51K	-7.09M	27.18M	10.85M	7.32M	6.4M	3.91M	14.62M	640K	807K
Gross Margin %	-	-6.15%	0.98%	0.59%	1.08%	0.96%	0.72%	0.81%	0.33%	1.83%
Gross Profit Growth %	1%	-300.43%	4.84%	-0.6%	-0.33%	-0.13%	-0.39%	2.74%	-0.96%	0.26%
Operating Expenses+	11.01M	17.23M	13.29M	29.52M	23.45M	6.4M	86.04M	52.06M	27.99M	69.32M
OpEx % of Revenue	-	14.95%	0.48%	1.61%	3.47%	0.96%	15.94%	2.88%	14.55%	157.19%
Selling, General & Admin	4.42M	7.08M	8.91M	19.2M	11.61M	19.76M	24.66M	20.71M	10.3M	17.24M
SG&A % of Revenue	-	6.14%	0.32%	1.05%	1.72%	2.95%	4.57%	1.15%	5.35%	39.1%
Research & Development	6.59M	10.15M	4.37M	5.79M	11.76M	32.19M	59.84M	31.31M	13.78M	52.08M
R&D % of Revenue	-	8.8%	0.16%	0.32%	1.74%	4.81%	11.08%	1.73%	7.16%	118.09%
Other Operating Expenses	0	0	0	13.66K	83.11K	-45.55M	1.55M	38K	3.91M	0
Operating Income+	-11.01M	-16.08M	13.89M	-39.31M	-16.14M	0	-82.13M	-37.44M	-27.35M	-68.51M
Operating Margin %	-	-13.95%	0.5%	-2.15%	-2.39%	-	-15.22%	-2.07%	-14.22%	-155.36%
Operating Income Growth %	0.36%	-0.46%	1.86%	-3.83%	0.59%	1%	-	0.54%	0.27%	-1.5%
EBITDA+	-10.99M	-16.05M	14.32M	-37.46M	-12.25M	-45.45M	-80.48M	-37.27M	-27.19M	-68.34M
EBITDA Margin %	-	-13.92%	0.51%	-2.04%	-1.82%	-6.78%	-14.91%	-2.06%	-14.13%	-154.97%
EBITDA Growth %	0.36%	-0.46%	1.89%	-3.62%	0.67%	-2.71%	-0.77%	0.54%	0.27%	-1.51%
D&A (Non-Cash Add-back)	23.51K	26.86K	425.48K	1.85M	3.88M	1.84M	1.66M	166K	158K	169K
EBIT	-10.48M	-16.08M	13.89M	-14.9M	-17.39M	-47.29M	-82.13M	-37.44M	-23.44M	-68.51M
Net Interest Income+	-793.21K	-464.18K	-24.02K	16.26K	121.33K	49K	-2.39M	-4.17M	-3.42M	3.32M
Interest Income	0	0	0	16.26K	121.33K	49K	0	0	0	3.32M
Interest Expense	793.21K	464.18K	24.02K	0	0	0	2.39M	4.17M	3.42M	0
Other Income/Expense	519.84K	-391.56K	-53.64K	54.93K	147.29K	-67.18M	-2.41M	-4.19M	-4.18M	33.5M
Pretax Income+	-10.49M	-16.47M	13.84M	-40.09M	-15.99M	-67.18M	-84.55M	-41.63M	-31.53M	-35.02M
Pretax Margin %	-	-14.29%	0.5%	-2.19%	-2.37%	-10.03%	-15.66%	-2.31%	-16.39%	-79.4%
Income Tax+	-543.51K	364.14K	1.97M	-33.91K	280.32K	-2.79M	-196K	28K	14K	114K
Effective Tax Rate %	1%	1%	0.86%	1%	1.01%	0.95%	1%	1%	1%	1%
Net Income+	-10.49M	-16.47M	11.87M	-40.05M	-16.07M	-63.5M	-84.38M	-41.66M	-31.54M	-35.13M
Net Margin %	-	-14.29%	0.43%	-2.19%	-2.38%	-9.48%	-15.63%	-2.31%	-16.4%	-79.66%
Net Income Growth %	0.35%	-0.57%	1.72%	-4.37%	0.6%	-2.95%	-0.33%	0.51%	0.24%	-0.11%
Net Income (Continuing)	-10.49M	-16.47M	11.87M	-35.27M	-16.27M	-64.38M	-84.35M	-41.66M	-31.54M	-35.13M
Discontinued Operations	0	0	0	0	198.21K	884K	-27K	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-16.21	-21.93	1822.74	-3317.28	-819.74	-2523.77	-2330.66	-1062.65	-113.58	-3.26
EPS Growth %	0.61%	-0.35%	84.12%	-2.82%	0.75%	-2.08%	0.08%	0.54%	0.89%	0.97%
EPS (Basic)	-16.21	-21.93	1856.88	-3317.28	-819.74	-2523.77	-2330.66	-1062.65	-113.58	-4.32
Diluted Shares Outstanding	773	3.07K	6.51K	12.07K	19.85K	25.51K	36.19K	39.2K	277.73K	10.78M
Basic Shares Outstanding	773	3.07K	6.39K	12.07K	19.85K	25.51K	36.19K	39.2K	277.73K	8.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.62M	5.66M	10.99M	21.93M	17.72M	26M	61.84M	16.42M	8.39M	138.89M
Cash & Short-Term Investments	21.16M	5.13M	2.47M	10.65M	11.24M	18.92M	54.59M	13.17M	7.42M	134.55M
Cash Only	21.16M	5.13M	2.47M	10.65M	3.61M	18.92M	54.59M	13.17M	7.42M	134.55M
Short-Term Investments	0	0	0	0	7.63M	0	0	0	0	0
Accounts Receivable	0	132.47K	2.94M	6.08M	5.24M	4.38M	4.8M	1.92M	136K	611K
Days Sales Outstanding	-	41.94	38.52	121.18	283.45	238.92	324.5	38.8	25.8	505.7
Inventory	0	11K	382.15K	1.11M	21.33K	3K	38K	20K	0	0
Days Inventory Outstanding	-	0.49	219.44	54.22	-13.75	3.65	9.3	2.13	-	-
Other Current Assets	58.83K	11.11K	4.18M	9.41M	515.11K	38K	51K	1.3M	844K	3.73M
Total Non-Current Assets+	35K	106K	32.13M	48.32M	18.38M	17.75M	18.37M	16.95M	12.6M	11.84M
Property, Plant & Equipment	35K	43K	44.61K	586.51K	1.45M	1.61M	2.69M	2.41M	1.97M	1.21M
Fixed Asset Turnover	-	26.81x	623.45x	31.25x	4.66x	4.17x	2.00x	7.49x	0.98x	0.36x
Goodwill	0	0	14.29M	16.41M	14.41M	14.41M	14.41M	14.41M	10.5M	10.5M
Intangible Assets	0	0	17.66M	31.24M	2.43M	1.58M	38K	0	0	0
Long-Term Investments	0	62.83K	131.35K	81.72K	0	0	0	0	0	0
Other Non-Current Assets	0	173	131.35K	-91.24K	101.94K	149K	1.23M	131K	131K	131K
Total Assets+	21.66M	5.77M	43.12M	70.25M	36.11M	43.76M	80.21M	33.37M	20.99M	150.73M
Asset Turnover	-	0.20x	0.64x	0.26x	0.19x	0.15x	0.07x	0.54x	0.09x	0.00x
Asset Growth %	0.76%	-0.73%	6.48%	0.63%	-0.49%	0.21%	0.83%	-0.58%	-0.37%	6.18%
Total Current Liabilities+	5.85M	4.31M	11.41M	26.22M	12.16M	15.22M	19.89M	22.11M	4.62M	6.96M
Accounts Payable	678.11K	1.01M	1.3M	1.45M	2.08M	2.57M	3.37M	2.88M	446K	283K
Days Payables Outstanding	10.53K	44.75	745.9	70.58	-1.34K	3.13K	824.74	306.33	126.78	-282.23
Short-Term Debt	3.21M	2.35M	0	0	0	0	0	5.93M	0	0
Deferred Revenue (Current)	1000K	942.57K	0	1000K	0	0	0	88K	0	0
Other Current Liabilities	835.56K	675.39K	8.71M	21.14M	5.57M	4.57M	4.32M	3.18M	3.06M	3.24M
Current Ratio	3.70x	1.31x	0.96x	0.84x	1.46x	1.71x	3.11x	0.74x	1.82x	19.96x
Quick Ratio	3.70x	1.31x	0.93x	0.79x	1.46x	1.71x	3.11x	0.74x	1.82x	19.96x
Cash Conversion Cycle	-	-2.33	-487.94	104.81	1.61K	-2.89K	-490.94	-265.4	-	-
Total Non-Current Liabilities+	8.57M	1.25M	3.86M	23.13M	2.95M	3.97M	37.24M	22.17M	9.07M	10.74M
Long-Term Debt	2.35M	0	0	0	0	0	32.83M	13.49M	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	7.14K	69.24K	85.98K	90K	113K	141K	155K	270K
Other Non-Current Liabilities	370.54K	1.25M	3.85M	23.06M	2.87M	3.88M	4.3M	8.54M	8.92M	10.47M
Total Liabilities	8.57M	5.56M	15.26M	49.34M	15.11M	19.19M	57.13M	44.28M	13.69M	17.7M
Total Debt+	5.56M	2.35M	0	15.38M	155.81K	426K	33.32M	19.95M	537K	568K
Net Debt	-15.6M	-2.77M	-2.47M	4.73M	-3.45M	-18.49M	-21.27M	6.78M	-6.88M	-133.98M
Debt / Equity	0.43x	11.37x	-	0.74x	0.01x	0.02x	1.44x	-	0.07x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-0.17x	-	-	-	-	-	-	-
Interest Coverage	-13.88x	-34.64x	578.36x	-	-	-	-34.35x	-8.98x	-8.00x	-
Total Equity+	13.08M	207K	27.86M	20.91M	21M	24.56M	23.08M	-10.91M	7.3M	133.03M
Equity Growth %	1.5%	-0.98%	133.59%	-0.25%	0%	0.17%	-0.06%	-1.47%	1.67%	17.21%
Book Value per Share	16927.91	67.51	4278.14	1731.63	1057.76	962.80	637.78	-278.43	26.30	12.34
Total Shareholders' Equity	13.08M	207K	27.86M	20.91M	21M	24.56M	23.08M	-10.91M	7.3M	133.03M
Common Stock	8.65K	9.43K	2.69M	40.8K	44.38K	75K	9K	0	1K	10K
Retained Earnings	-53.56M	-70.04M	-58.17M	-98.22M	-114.29M	-177.79M	-262.17M	-303.82M	-335.13M	-370.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-21.66B	0	2.66M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.16M	-14.57M	12.52M	-3.13M	-19.13M	-40.54M	-70.89M	-26.75M	-30.68M	-49.06M
Operating CF Margin %	-	-12.64%	0.45%	-0.17%	-2.83%	-6.05%	-13.13%	-1.48%	-15.95%	-111.24%
Operating CF Growth %	0.35%	-0.43%	1.86%	-1.25%	-5.12%	-1.12%	-0.75%	0.62%	-0.15%	-0.6%
Net Income	-10.49M	-16.47M	11.87M	-40.05M	-16.07M	-63.5M	-84.38M	-41.66M	-31.54M	-35.13M
Depreciation & Amortization	23.51K	26.86K	425.48K	4.55M	3.88M	1.84M	1.66M	166K	158K	169K
Stock-Based Compensation	394.75K	1.69M	1.16M	2.43M	2.53M	6.79M	8.17M	0	3.48M	5.85M
Deferred Taxes	-1.31M	-72.63K	-832.63K	-16.75K	16.74K	197K	22K	28K	14K	114K
Other Non-Cash Items	293.75K	162.27K	366.23K	21.22M	-7.47M	18.57M	794K	14.77M	6.46M	-15.35M
Working Capital Changes	927.77K	87.07K	-466.75K	8.73M	-2.03M	-4.44M	2.84M	-60K	-9.24M	-4.71M
Change in Receivables	0	-132.47K	-247.19K	-222.53K	6.78M	-2.79M	1.12M	2.88M	1.78M	-475K
Change in Inventory	0	0	-202.62K	-311.2K	532.95K	18K	-35K	18K	20K	0
Change in Payables	-268.71K	332.1K	96.06K	82.45K	1.02M	99K	796K	-487K	-2.44M	-163K
Cash from Investing+	-19.98K	-34.88K	-18.91M	865.46K	-443K	11.13M	-113K	-95K	-133K	356K
Capital Expenditures	-19.98K	-34.88K	-23.32K	-564.41K	-262.01K	-63K	-113K	-95K	-158K	0
CapEx % of Revenue	-	0.03%	0%	0.03%	0.04%	0.01%	0.02%	0.01%	0.08%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-1K	-180.99K	0	0	0	25K	0
Cash from Financing+	19.6M	-1.43M	3.74M	10.4M	12.56M	44.78M	106.76M	-14.7M	25.04M	175.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.27M	-114.94K	-232.38K	6.55M	131.07K	332K	1.93M	0	67K	60.22M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.18M	-14.61M	12.5M	-3.69M	-19.4M	-40.6M	-71M	-26.85M	-30.84M	-49.06M
FCF Margin %	-	-12.67%	0.45%	-0.2%	-2.87%	-6.06%	-13.15%	-1.49%	-16.03%	-111.24%
FCF Growth %	0.34%	-0.43%	1.86%	-1.3%	-4.25%	-1.09%	-0.75%	0.62%	-0.15%	-0.59%
FCF per Share	-13175.11	-4764.35	1918.91	-305.82	-977.20	-1591.55	-1961.95	-684.81	-111.04	-4.55
FCF Conversion (FCF/Net Income)	0.97x	0.88x	1.05x	0.08x	1.19x	0.64x	0.84x	0.64x	0.97x	1.40x
Interest Paid	0	0	72.53K	525K	1.05M	0	0	0	0	0
Taxes Paid	0	0	540K	354K	1.8M	474K	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-80.17%	-247.85%	84.58%	-164.26%	-76.71%	-278.77%	-354.19%	-684.77%	-431.87%	-50.06%
Return on Invested Capital (ROIC)	-	-	91.3%	-115.57%	-56.06%	-	-1562.67%	-	-4815.32%	-
Gross Margin	-	-614.57%	97.71%	59.19%	108.39%	95.52%	72.38%	80.98%	33.26%	182.99%
Net Margin	-	-1428.53%	42.68%	-218.55%	-238.1%	-947.9%	-1563.1%	-230.78%	-1639.5%	-7965.76%
Debt / Equity	0.43x	11.37x	-	0.74x	0.01x	0.02x	1.44x	-	0.07x	0.00x
Interest Coverage	-13.88x	-34.64x	578.36x	-	-	-	-34.35x	-8.98x	-8.00x	-
FCF Conversion	0.97x	0.88x	1.05x	0.08x	1.19x	0.64x	0.84x	0.64x	0.97x	1.40x
Revenue Growth	-	-	2312.24%	-34.11%	-63.17%	-0.76%	-19.42%	234.4%	-89.34%	-77.08%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	6.7M	4.77M	3.36M	1.41M	441K
Product Growth	-	-	-	-28.75%	-29.52%	-58.15%	-68.68%
License	-	100K	-	625K	14.69M	516K	-
License Growth	-	-	-	-	2249.92%	-96.49%	-
Prescription Drugs	10.19M	6.65M	-	-	-	-	-
Prescription Drugs Growth	-	-34.75%	-	-	-	-	-
Sales Revenue, Product	17.87M	6.65M	-	-	-	-	-
Sales Revenue, Product Growth	-	-62.79%	-	-	-	-	-
Sales Force Revenue	456.06K	-	-	-	-	-	-
Sales Force Revenue Growth	-	-	-	-	-	-	-
Prescribed Dietary Supplements	7.68M	-	-	-	-	-	-
Prescribed Dietary Supplements Growth	-	-	-	-	-	-	-
Grant Revenue	-	-	-	-	-	-	-
Grant Revenue Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Avalo Therapeutics, Inc. (AVTX) reported $0.2M in revenue for fiscal year 2024. This represents a 132% increase from $0.1M in 2012.

Avalo Therapeutics, Inc. (AVTX) saw revenue decline by 77.1% over the past year.

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $99.9M for fiscal year 2024.

Dividend & Returns

Avalo Therapeutics, Inc. (AVTX) has a return on equity (ROE) of -50.1%. Negative ROE indicates the company is unprofitable.

Avalo Therapeutics, Inc. (AVTX) had negative free cash flow of $52.3M in fiscal year 2024, likely due to heavy capital investments.